Wake Forest University Health Sciences

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Wake Forest University Health Sciences sits in the top decile of US sponsors by registered trial count (#27 of 15,742 sponsors by registered trial count).

1,140 total trials 174 currently recruiting 724 completed early-phase tilt top decile by trial count

Wake Forest University Health Sciences: 1,140 sponsored US clinical trials, 174 recruiting.

Wake Forest University Health Sciences sponsors 1,140 registered US clinical trials on ClinicalTrials.gov, 174 of them currently recruiting, and 724 completed. 111 of these trials are in Phase 3-4 (later-stage) and 239 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 9 trials.

Top-decile sponsor footprint

Wake Forest University Health Sciences ranks in the top decile of sponsors by registered trial count (#27 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 44/100

724 of 885 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,140 total, page 18 of 23

COMPLETED NA

Cervical Ripening With a Double-lumen Balloon Catheter for Six Versus Twelve Hours

NCT03086967

COMPLETED NA

Project 1, Study 1: Investigating the Impact of Nicotine Using Spectrum Cigarettes

NCT01681875

COMPLETED Phase 4

Does Oral Micronized Progesterone Shorten Time of Symptoms From Concussion

NCT01809639

TERMINATED NA

Does Less Trendelenburg Make a Difference in Robotic Assisted Gynecological Procedures?

NCT02728999

COMPLETED

Persistent Pain After CS Delivery

NCT01996592

COMPLETED Phase 1

CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery

NCT01766219

COMPLETED

Using Serum Parathyroid Hormones and Calcium to Improve Prostate Cancer Diagnosis

NCT02397629

TERMINATED NA

Atrial Pressure Electrophysiology Pilot Study

NCT01845974

COMPLETED Phase 4

Adductor Canal Block for Medial Compartment Knee Arthroplasty

NCT01818531

COMPLETED NA

Feasibility of Upright Bed Position in ARDS Patients

NCT02160561

COMPLETED NA

A Randomized, Controlled Trial of Inspiratory Muscle Training (IMT)in the ICU and CCU

NCT02003053

COMPLETED NA

Foley Catheter for Induction of Labor

NCT02044458

COMPLETED Phase 1

CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer

NCT01835041

TERMINATED

Superior Laryngeal Nerve Block For Awake Endotracheal Intubation Study

NCT01848548

COMPLETED NA

Macronutrient Effects on Alzheimer's Disease (MEAL-2)

NCT02463084

COMPLETED NA

Parents and Children Together Preventing Diabetes (PACT PD)

NCT01819493

COMPLETED

Pelvic CT Imaging in Blunt Abdominal Trauma

NCT01828749

COMPLETED NA

Evidence-Based Tobacco Cessation Strategies in Patients With Cancer

NCT02211196

COMPLETED Phase 4

Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases

NCT02040116

COMPLETED NA

MRI in Detecting Heart Damage in Patients With Cancer Receiving Chemotherapy With Exercise Capacity Addendum

NCT01719562

COMPLETED NA

Bovine Lactoferrin in Reducing Taste Disturbances in Patients With Colorectal Cancer Receiving Oxaliplatin-Based Chemotherapy

NCT01596634

COMPLETED

Evaluation of Efficacy and Accuracy of a Cordless Ultrasonic Dissection System

NCT01929928

COMPLETED Phase 1

CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT01768897

COMPLETED NA

Almased Multi-Center Diabetes Intervention Trial

NCT01702012

COMPLETED

Are Serial Electrocardiograms Additive to SeriAl Second-generations Troponins in Predicting Acute CoronAry Syndromes in PatienTs With Undifferentiated cHest Pain

NCT01953276

TERMINATED NA

The Effect of Botulinum Toxin A Injections on Ankle Dorsiflexion Following Internal Fixation of Tibial Pilon Fractures

NCT02051933

COMPLETED NA

Trial of Acupuncture for Radiation-Induced Xerostomia in Head and Neck Cancer

NCT02589938

COMPLETED

Using Ultrasound to Study Respiratory Muscle Function in Critically Ill Patients

NCT03139695

COMPLETED

Muscle Ultrasound Signifies Condition Upgrade Leading Approach to Recovery

NCT02014285

TERMINATED Early Phase 1

Update and Biodistribution of [F-18]FMDHT pET/CT in Normal Healthy Volunteers and Patients With Metastatic Prostate Cancer - A First in Human Subject Study With [F-18] FMDHT

NCT01724619

TERMINATED NA

The Use of Biologic Mesh vs Bioabsorbable Mesh During Ventral Hernia Repair in At-risk Patients

NCT01794338

COMPLETED NA

Symptom-Adapted Physical Activity Intervention in Minimizing Physical Function Decline in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy

NCT01519596

COMPLETED Phase 3

The Use of Tranexamic Acid to Reduce Blood Loss in Acetabular Surgery

NCT02684851

COMPLETED NA

Efficacy Evaluation of the HEART Pathway in Emergency Department Patients With Acute Chest Pain

NCT01665521

COMPLETED

Ankle Fracture vs Ankle Fracture-Dislocation

NCT02198768

COMPLETED Phase 2

Memantine Hydrochloride in Helping Cancer Survivors Stop Smoking

NCT01535040

COMPLETED

RITHM - Resonance Imaging Trial for Heart Biomarkers in Adolescent/Young (AYA) Cancer Survivors

NCT01719094

COMPLETED

MRI to Assess the Effects of Dysautonomia and Chronic Nausea on Brain Transmitters

NCT01692561

COMPLETED NA

Evaluating Sexual Function After Vaginal Repair With Perineorrhaphy

NCT01779739

COMPLETED NA

Stereotactic Radiation to Decrease Pancreatic Secretions

NCT01656486

COMPLETED Phase 2

Dietary Nitrate Supplements and Ischemic Stroke Recovery

NCT02838901

COMPLETED NA

Negative Pressure Therapy in Preventing Infection After Surgery in Patients With Colon, Rectal, Pancreatic, or Peritoneal Surface Cancer

NCT01656044

COMPLETED NA

Effectiveness of Web-based Teaching to Traditional Patient Education in the Use of Injectable Fertility Medications

NCT02420964

COMPLETED

Molecular and Diagnostic Classification of Non-Small Cell Lung Cancer From Fine Needle Aspirates

NCT01630122

COMPLETED Phase 2

Local Anesthetic Cream in Younger Patients Undergoing Lumbar Punctures

NCT01516684

COMPLETED NA

Mindful Movement and Breathing to Improve Outcomes of Gynecologic Surgery

NCT01593657

COMPLETED

Mild Traumatic Brain Injury Registry

NCT01688869

COMPLETED

Surgical Outcomes Database For Faculty of Hepatopancreatic Biliary Surgery

NCT01657383

COMPLETED Early Phase 1

Remote Ischemic Preconditioning Mechanism Study

NCT01541436

COMPLETED NA

Cooperative Lifestyle Programs (CLIP-II)

NCT01547182

← Previous Page 18 of 23 Next →

Phase Distribution

PhaseTrial count
Phase 1 96
Phase 2 143
Phase 3 31
Phase 4 80

What is open in the Wake Forest University Health Sciences pipeline

174 recruiting of 1,140 indexed (15% open); 724 completed (64%).

Phase mix: 111 late (III/IV) vs 239 early (I/II) (early-phase heavy).

Top condition: Breast Cancer (9 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Wake Forest University Health Sciences: open-pipeline peers nationwide

Peers matched on 1,140 registered trials and 15% open enrollment, not the therapeutic-area sidebar.

Wake Forest University Health Sciences sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 8%10%12%14%16%18%20% Total trials Recruiting share Wake Forest University Health SciencesUniversity of Alabama at BirminghamNYU Langone HealthUniversity of North Carolina, Chapel HillUniversity of FloridaBaylor UniversityCornell UniversityArrowhead Regional Medical CenterAurinia Pharmaceuticals
Wake Forest University Health Sciences sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Wake Forest University Health Sciences sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,140 trials (± recruiting share)

Sponsors near 15% open enrollment (± trial volume)

What to do with this Wake Forest University Health Sciences page

1,140 registered trials is a research-attention snapshot, not an endorsement of Wake Forest University Health Sciences or any single study.

  • 174 of Wake Forest University Health Sciences's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Breast Cancer is the condition Wake Forest University Health Sciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Wake Forest University Health Sciences pipeline card: 1,140 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.